“BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA”. Mediterranean Journal of Hematology and Infectious Diseases, vol. 8, Feb. 2016, p. e2016011, https://doi.org/10.4084/mjhid.2016.011.